In addition, we can continue to explore the use of 38C13 cell transformation for the study of other EBV antigen vaccines like LMP2, which is also a surface-expressed antigen, and the nuclear antigen EBNA1, in order to validate new protective antigens and establish combination vaccines targeting EBV+ tumor cells. Here, PSMB9 is linked to neoplasm.